What retatrutide is, in plain English
Retatrutide is an experimental injectable drug being studied for obesity and type 2 diabetes. The FDA has not approved it. It acts on three hormone receptors at once instead of one or two. Today it exists only inside clinical research. No US pharmacy can lawfully dispense it, and no telehealth clinician can prescribe it.
The compound was developed by Eli Lilly and carries the research code LY3437943. In trial documents you will also see it called a triple hormone receptor agonist, or a peptide, because the molecule is a short chain of amino acids rather than a small chemical pill. That is the same broad family as the injectable diabetes and weight drugs already on the market.
Search interest is unusually high for a drug nobody can buy at a pharmacy counter. Early study results were striking, so the name spread through news coverage and social media well ahead of any approval decision. The maker has been direct about its status, stating on its own site that the drug is still investigational and not available for public use, in a plain company explainer published on the Lilly newsroom page about the compound.
Investigational has a specific meaning. It means the drug is being tested under an FDA application that allows research use only. Safety and effectiveness have not been established for general use. Dosing, warnings, contraindications and long term risks have not been finalised in an approved label. That single fact shapes everything else on this page, including cost, access and safety.
If you are comparing what is actually prescribable right now, the Medication Index covers the approved injectables patients are more likely to be offered.
How a triple hormone agonist works in the body
Most weight and diabetes injectables copy one or two gut hormones. This one copies three. It stimulates the GLP-1 receptor, the GIP receptor and the glucagon receptor. Each one pushes a different lever, which is why researchers are interested in the combination.
GLP-1 is the hormone most people have heard of. Activating its receptor slows how fast the stomach empties, increases the feeling of fullness after eating, and prompts the pancreas to release insulin when blood sugar rises. That is the mechanism behind the current generation of weekly injections.
GIP is a second gut hormone released after meals. It also affects insulin release and appears to influence appetite signalling in the brain and how fat tissue handles energy. Adding GIP activity to GLP-1 activity is the design behind the dual agonist already approved for diabetes and weight management.
Glucagon is the unusual addition. Glucagon is usually thought of as the hormone that raises blood sugar. Stimulating its receptor also increases energy expenditure and encourages the liver to burn stored fat. Researchers are testing whether the appetite suppression from GLP-1 and GIP can offset glucagon’s tendency to push glucose up, leaving a net gain in fat loss and liver fat reduction. A published academic review of the mechanism and early data is available through the NIH PubMed Central archive.
That three way design is also why the safety profile cannot simply be assumed from existing drugs. Glucagon receptor activity is not part of the approved GLP-1 or dual agonist medicines, so its effects on heart rate, blood sugar control and long term organ health are still being measured.
What the clinical trials have reported so far
The headline data came from a phase 2 study in adults with obesity, published in a major medical journal. Over 48 weeks, participants on the highest dose lost roughly a quarter of their starting body weight on average, with clear dose dependent differences between groups. The full trial report is published in the New England Journal of Medicine.
Phase 2 is a mid stage trial. It is designed to find a workable dose range and spot common side effects, not to prove long term safety or benefit. Separate phase 2 work looked at adults with type 2 diabetes, measuring blood sugar control alongside weight. A larger phase 3 program is underway, and registered studies for the compound can be looked up in the federal ClinicalTrials.gov registry.
People searching for a dosing chart or a dose calculator will not find a validated one, because there is no approved label to base it on. Trials used a once weekly injection under the skin, with the dose stepped up slowly over months to limit stomach side effects. Those escalation schedules are research protocols run under medical supervision, not instructions any individual should copy.
Trial results also do not transfer neatly to real life. Participants are screened, monitored, given structured lifestyle support and followed closely. Average results hide wide individual variation, and some people in any trial stop early because of side effects. Treat published averages as a signal of promise, not a personal forecast.
Side effects, warnings and interaction risks
What showed up most often
Gastrointestinal effects dominated the reported adverse events. Nausea, vomiting, diarrhoea and constipation were common, tended to appear when the dose increased, and were generally worse at higher doses. Reduced appetite and fatigue were also reported. These match the pattern seen across the incretin drug class.
Signals worth taking seriously
Trial reports noted increases in heart rate at higher doses, which fits with glucagon receptor activity. Some participants reported unusual skin sensitivity. Blood sugar can drop too low when this kind of drug is combined with insulin or sulfonylurea tablets. Rapid vomiting or diarrhoea can also cause dehydration, which can strain the kidneys.
Drugs in the wider GLP-1 family carry approved label warnings about pancreatitis, gallbladder disease, severe stomach emptying problems and, in rodent studies, thyroid C cell tumours. Those approved products carry a boxed warning about thyroid tumours and are not used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. Investigational triple agonist trials apply similar exclusions. The agency’s plain summary of risks tied to this drug class, including unapproved versions, is set out in an FDA advisory on unapproved GLP-1 products.
Interactions and disclosure
Slower stomach emptying can change how fast swallowed medicines are absorbed. That matters for drugs with a narrow safety margin, for some oral contraceptives and for anything timed tightly to meals. Insulin and sulfonylureas may need review because of low blood sugar risk. Anaesthesia teams now routinely ask about incretin drugs before sedation, because food can remain in the stomach longer than expected. Because no approved interaction list exists for this compound, any interaction guidance is borrowed from the class and should be treated as incomplete. For patient level background on the approved options, Semaglutide Side Effects And Cost covers a labelled drug with a documented warning set.
Retatrutide compared with tirzepatide and semaglutide
The most common question is whether this is the same thing as Ozempic. It is not. Ozempic is a brand of semaglutide, a single hormone GLP-1 drug approved for type 2 diabetes. The experimental triple agonist targets three receptors and is approved for nothing. They are relatives, not twins.
Retatrutide vs Approved Alternatives
| Tirzepatide | Semaglutide | |
|---|---|---|
| Receptors targeted | GIP and GLP-1 | GLP-1 only |
| US status | FDA approved | FDA approved |
| How given | Weekly injection | Weekly injection or oral tablet |
| Oral form available | No | Yes |
| Compound | Receptors targeted | US status | How it is given |
|---|---|---|---|
| Retatrutide | GIP, GLP-1 and glucagon | Investigational, trials only | Weekly injection in studies |
| Tirzepatide | GIP and GLP-1 | FDA approved brands available | Weekly injection |
| Semaglutide | GLP-1 only | FDA approved brands available | Weekly injection, oral tablet form exists |
Is it a fat burner? Not in the supplement sense. It does not work by stimulating the nervous system. The glucagon component may raise energy expenditure, but the main published effect on weight comes from eating less because appetite and fullness signals change.
People also ask about an oral version. Approved oral options exist in this drug class, but the triple agonist has been studied as an injection. Any product marketed online as an oral or nasal version of it is not a tested formulation. Readers weighing approved alternatives can start with How Tirzepatide Is Used, then compare programs in Choosing A GLP-1 Program.
Cost: what can and cannot be quoted
There is no legitimate US self-pay price for this compound, because it is not sold through licensed pharmacies. Anyone quoting a monthly figure is either describing a grey market vial or guessing at a future launch price. Neither is a real cost you can plan around.
Trial participation is a different matter. In registered studies, the study drug and study visits are normally provided at no charge to the participant, though travel and time are your own cost. That is standard research practice, not a discount program.
For a realistic sense of what this category costs today, look at the approved molecules the directory actually tracks. The lowest self-pay price tracked for semaglutide is $99 a month, and the lowest tracked for tirzepatide is $99 a month. Those figures move often, so treat them as a snapshot rather than a fixed rate.
What moves a monthly number in this category is fairly predictable: brand product versus a compounded preparation, the pharmacy filling it, the dose strength, whether labs and clinician visits are bundled into the membership, and whether an introductory rate steps up at renewal. Insurance is its own separate track, and prior authorisation refusals for weight medicines are common rather than unusual, so verify with your own plan before assuming anything.
Annual maths tends to be more useful than monthly maths for a treatment people stay on for a long time.
What a year actually costs
Programmes quote a monthly headline. Add the medication, the labs and the renewal price and the real number is usually different.
Advertised prices change often and intro pricing rarely lasts. Ask what the renewal rate is before you commit to a plan.
If you want the cost comparison laid out across programs rather than one at a time, the Free Savings Report shows the format, and the Telehealth Provider Directory lists who offers what.
How people are actually getting it, and where that goes wrong
There are only two honest routes, and one of them is not a route at all.
- Join a registered clinical trial. Studies list eligibility criteria such as age, body mass index, diabetes status and excluded medical history. Screening is thorough and most volunteers who apply do not qualify.
- Wait for a regulatory decision. Until an approval exists, no clinician can prescribe it and no pharmacy can fill it.
Compounding does not create a third route. US compounding rules limit what a pharmacy may make from bulk ingredients, generally requiring the substance to be a component of an approved drug, to have a recognised monograph, or to appear on a specific FDA list. An investigational molecule that has never been approved does not meet those conditions. The framework is described in the FDA overview of human drug compounding.
That leaves the grey market. Vials are sold online as research chemicals, often labelled not for human consumption, shipped as powder to be mixed by the buyer. Nothing about that supply chain is regulated for sterility, purity, potency or accurate labelling. Independent testing of similar peptide products has found contents that do not match the label. The buyer also becomes their own pharmacist, reconstituting powder and calculating units with no professional check. FDA has warned repeatedly about unapproved and counterfeit versions of weight loss injectables, including its notice on semaglutide products sold outside approved channels.
Expanded access, sometimes called compassionate use, applies to serious or life threatening illness when no comparable option exists and a company agrees to supply the drug. It is not a general pathway to weight treatment. The criteria are explained in the FDA expanded access program materials.
If body mass index is part of the eligibility question you are researching, this calculator gives the number trials and clinics usually screen on.
BMI calculator
Most weight-loss programmes screen on BMI before they will prescribe. This is the number they will use.
A screening number, not a diagnosis. It does not distinguish muscle from fat, and it reads high for muscular builds.
Broader coverage of how weight programs operate, what they include and where patients report friction sits in our Weight Loss Reporting, and the scoring behind provider pages is documented in How Our Scores Work.
Questions worth asking, and when to seek care
If a clinician or program raises this compound with you, a few direct questions clear things up fast.
Questions to Ask Before Pursuing Any GLP-1 Program
- Is this an approved medicine or an investigational one?
- Which pharmacy prepares it, and under what licence?
- What approved options fit my health history?
- Has thyroid, pancreatitis, and gallbladder history been screened?
- How will side effects be handled between visits?
- What is included in the monthly cost, and does the rate change after the first months?
- Is this an approved medicine, or an investigational one? Ask them to say it plainly.
- Which pharmacy prepares what you are being offered, and under what licence?
- What approved options fit my health history, and why would we skip them?
- What screening happens first: thyroid history, pancreatitis history, gallbladder problems, kidney function, current medicines?
- How will side effects be handled, and who do I contact between visits?
- What is included in the monthly cost, and does that rate change after the first months?
If you are considering a trial, ask the study team about the time commitment, what happens after the study ends, and whether you may receive a placebo. Ask what monitoring is done and who pays if a complication arises.
General red flags apply to any drug in this class. Severe or constant stomach pain that spreads to the back, with or without vomiting, needs urgent assessment. So do persistent vomiting with signs of dehydration, yellowing of the skin or eyes, a neck lump or hoarseness that does not settle, and any sign of a serious allergic reaction such as swelling of the face or throat or trouble breathing. Symptoms of very low blood sugar, including shaking, confusion and sweating, need prompt attention, especially alongside insulin. Call emergency services for breathing difficulty, chest pain or collapse.
Anyone who is pregnant, trying to conceive or breastfeeding should not use investigational or unapproved weight drugs, and should raise the topic with a clinician before starting anything in this category. Tools that help you track numbers between appointments are collected in our Free Health Calculators.
Authoritative sources
- Phase 2 obesity trial results, reported in the New England Journal of Medicine.
- Federal safety guidance on unapproved weight loss injectables, published by the US Food and Drug Administration.
- Patient level background on weight management options, from the NIH diabetes and digestive institute.
Educational content, not medical advice. Always consult a qualified clinician before starting, stopping or switching treatment.
